Defibrotide for the prevention and treatment of cytokine release syndrome and neurotoxicity associated with immunodepletion

Abstract

The present disclosure provides method of preventing, lessening the effects, or treating cytokine release syndrome (CRS) or related disorders, and / or neurotoxicity associated with immunotherapy comprising administering defibrotide. The defibrotide can be administered after the immunotherapy begins or be administered prophylactically before immunotherapy begins or before the patient develops CRS and / or neurotoxicity.

Description

technical field [0001] The present disclosure relates to methods of administering defibrotide to prevent and / or treat cytokine release syndrome (CRS) and / or neurotoxicity associated, inter alia, with CAR-T or bispecific antibody therapy. Background technique [0002] Immunotherapy, including the use of lymphocyte depletion or monoclonal antibodies, has become an important tool in cancer and tumor treatment. T cells expressing chimeric antigens (CAR-T cells) and bispecific antibodies are becoming options for lymphocyte depletion. However, while these therapies show promise, treatment with CAR-T cells or bispecific antibodies can lead to massive and rapid release of cytokines into the blood and cause cytokine release syndrome (CRS) or CAR-T cell-associated Encephalopathy syndrome (CRES) [also referred to herein as CAR-T-associated neurotoxicity or ICANS (immune effector cell (IEC) therapy-associated neurotoxicity syndrome)]. [0003] CRS is characterized by high fever, hypot...

AI Technical Summary

Problems solved by technology

However, while these therapies show promise, treatment with CAR-T cells or bispecific antibodies can lead to massive and rapid release of cytokines into the blood and cause cytokine release syndrome (CRS) or CAR-T cell-associated Encephalopathy syndrome (CRES) [herein also referred to as CAR-T-associated neurotoxicity or ICANS (immune effector cell (IEC) therapy-associated neurotoxicity syndrome)]

Images